For the second year in a row, biotech put together a strong showing in the first quarter with all market segments gaining ground. The sector was led by mid-caps, which closed up 16%.

Large caps were close behind with a 15% gain, marking three straight quarters in the black. Celgene Corp. was up 48% for the quarter, the strongest showing in the $5 billion-plus tier.